InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,264.00
(
-0.74%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
85.02
(
0.38%
)
Bitcoin
65,082.92
(
0.18%
)
Post# of 252273
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: jq1234 post# 118068

Tuesday, 04/12/2011 2:52:09 AM

Tuesday, April 12, 2011 2:52:09 AM

Post# of 252273
Laquinimod results from the ALLEGRO study

Reduction in the relapse rate was as expected relatively weak but on efficacy Teva will emphasize the strong reduction in disability progression (measured by the EDSS scale) as only Avonex (not even Gilenya) among first line agents showed a slightly higher rate.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up